Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 12Nasopharyngeal Carcinoma 8Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 5Esophageal Neoplasms 5Recurrence 4Nasopharyngeal Neoplasms 4Lung Neoplasms 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Osteosarcoma 3Neuroblastoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3Small Cell Lung Carcinoma 2Peritoneal Neoplasms 2Neoplasms 2Hyperthermia 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vomiting 1Virus Diseases 1Tumor Virus Infections 1Tongue Neoplasms 1

Interventions

transplatin 1Platinum 1Gemcitabine 1Cystectomy 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Infiltrating Bladder Urothelial Carcinoma × Cisplatin × Clear all
NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡